Biologics for Psoriasis.
Psoriasis
/ drug therapy
Humans
Biological Products
/ therapeutic use
Ustekinumab
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antibodies, Monoclonal
/ therapeutic use
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Etanercept
/ therapeutic use
Adalimumab
/ therapeutic use
Infliximab
/ therapeutic use
Interleukin-17
/ antagonists & inhibitors
Dermatologic Agents
/ therapeutic use
Certolizumab Pegol
/ therapeutic use
Interleukin-23
/ antagonists & inhibitors
Interleukin-12
/ antagonists & inhibitors
Biologics
Efficacy
Psoriasis
Safety
Journal
Dermatologic clinics
ISSN: 1558-0520
Titre abrégé: Dermatol Clin
Pays: United States
ID NLM: 8300886
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
medline:
26
5
2024
pubmed:
26
5
2024
entrez:
25
5
2024
Statut:
ppublish
Résumé
Biologic therapies targeting tumor necrosis factor alpha (TNF-α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized the treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-α inhibitors.
Identifiants
pubmed: 38796266
pii: S0733-8635(24)00013-5
doi: 10.1016/j.det.2024.02.001
pii:
doi:
Substances chimiques
Biological Products
0
Ustekinumab
FU77B4U5Z0
Antibodies, Monoclonal, Humanized
0
Antibodies, Monoclonal
0
guselkumab
089658A12D
risankizumab
90ZX3Q3FR7
Tumor Necrosis Factor-alpha
0
tildrakizumab
DEW6X41BEK
secukinumab
DLG4EML025
Etanercept
OP401G7OJC
ixekizumab
BTY153760O
brodalumab
6ZA31Y954Z
Adalimumab
FYS6T7F842
Infliximab
B72HH48FLU
Interleukin-17
0
Dermatologic Agents
0
Certolizumab Pegol
UMD07X179E
Interleukin-23
0
Interleukin-12
187348-17-0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
339-355Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure J.M. Cohen serves on a data and safety monitoring board for Advarra. The remaining authors have no conflicts of interest to declare.